EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy



RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy



Human Gene Therapy Methods 24(4): 228-240



Over the last two decades, several attempts to generate packaging cells for lentiviral vectors (LV) have been made. Despite different technologies, no packaging clone is currently employed in clinical trials. We developed a new strategy for LV stable production based on the HEK-293T progenitor cells; the sequential insertion of the viral genes by integrating vectors; the constitutive expression of the viral components; and the RD114-TR envelope pseudotyping. We generated the intermediate clone PK-7 expressing constitutively gag/pol and rev genes and, by adding tat and rd114-tr genes, the stable packaging cell line RD2-MolPack, which can produce LV carrying any transfer vector (TV). Finally, we obtained the RD2-MolPack-Chim3 producer clone by transducing RD2-MolPack cells with the TV expressing the anti-HIV transgene Chim3. Remarkably, RD114-TR pseudovirions have much higher potency when produced by stable compared with transient technology. Most importantly, comparable transduction efficiency in hematopoietic stem cells (HSC) is obtained with 2-logs less physical particles respect to VSV-G pseudovirions produced by transient transfection. Altogether, RD2-MolPack technology should be considered a valid option for large-scale production of LV to be used in gene therapy protocols employing HSC, resulting in the possibility of downsizing the manufacturing scale by about 10-fold in respect to transient technology.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333959

Download citation: RISBibTeXText

PMID: 23767932

DOI: 10.1089/hgtb.2012.190



Related references

A new-generation stable inducible packaging cell line for lentiviral vectors. Human Gene Therapy 12(8): 981-997, 2001

Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18. Biotechnology Progress 15(5): 941-948, 1999

A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Molecular Therapy 14(2): 276-284, 2006

A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease. Human Gene Therapy 22(3): 357-369, 2011

Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. Journal of Gene Medicine 4(4): 347-355, 2002

Generation of a Vero-Based Packaging Cell Line to Produce SV40 Gene Delivery Vectors for Use in Clinical Gene Therapy Studies. Molecular Therapy. Methods & Clinical Development 6: 124-134, 2017

High-Titer Production of HIV-Based Lentiviral Vectors in Roller Bottles for Gene and Cell Therapy. Methods in Molecular Biology, 2018

Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Molecular Therapy 3(1): 97-104, 2001

Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. Molecular Therapy 8(4): 666-673, 2003

HIV-based lentiviral vectors for anti-HIV gene therapy. Future Virology 5(4): 367-369, 2010

Lentiviral vectors containing a retinal pigment epithelium specific promoter for leber congenital amaurosis gene therapy. Lentiviral gene therapy for LCA. Advances in Experimental Medicine and Biology 572: 247-253, 2007

Development of lentiviral vectors for anti-angiogenic gene therapy. Cancer Gene Therapy 7(12): S15, December, 2000

Modified HIV-based lentiviral vectors for anti-HIV gene therapy. Blood 94(10 SUPPL 1 PART 1): 361a, Nov 15, 1999

RNAi-inducing lentiviral vectors for anti-HIV-1 gene therapy. Methods in Molecular Biology 721: 293-311, 2011

Development of Novel Packaging Cell Lines for Generation of Adeno-Associated Virus Vectors by Lentiviral Gene Transfer of Trans-Complementary Components. Blood 100(11): Abstract No 2570, November 16, 2002